CN101801358A - 治疗性稳定的纳米颗粒 - Google Patents
治疗性稳定的纳米颗粒 Download PDFInfo
- Publication number
- CN101801358A CN101801358A CN200880024841A CN200880024841A CN101801358A CN 101801358 A CN101801358 A CN 101801358A CN 200880024841 A CN200880024841 A CN 200880024841A CN 200880024841 A CN200880024841 A CN 200880024841A CN 101801358 A CN101801358 A CN 101801358A
- Authority
- CN
- China
- Prior art keywords
- nano
- particle
- polymer
- polymeric layer
- chemical compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6933—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained by reactions only involving carbon to carbon, e.g. poly(meth)acrylate, polystyrene, polyvinylpyrrolidone or polyvinylalcohol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
- A61K47/6931—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer
- A61K47/6935—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle the material constituting the nanoparticle being a polymer the polymer being obtained otherwise than by reactions involving carbon to carbon unsaturated bonds, e.g. polyesters, polyamides or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Nanotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Optics & Photonics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
Claims (25)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US95972807P | 2007-07-16 | 2007-07-16 | |
US60/959,728 | 2007-07-16 | ||
PCT/US2008/070164 WO2009012303A2 (en) | 2007-07-16 | 2008-07-16 | Therapeutic stable nanoparticles |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101801358A true CN101801358A (zh) | 2010-08-11 |
Family
ID=40121219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN200880024841A Pending CN101801358A (zh) | 2007-07-16 | 2008-07-16 | 治疗性稳定的纳米颗粒 |
Country Status (6)
Country | Link |
---|---|
US (1) | US20110038939A1 (zh) |
EP (1) | EP2164475A2 (zh) |
JP (1) | JP2010533730A (zh) |
CN (1) | CN101801358A (zh) |
CA (1) | CA2694089A1 (zh) |
WO (1) | WO2009012303A2 (zh) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102175655A (zh) * | 2010-12-24 | 2011-09-07 | 东南大学 | 一种双模式光学成像探针及其制备方法 |
CN105283176A (zh) * | 2012-12-17 | 2016-01-27 | 圣地亚哥-德孔波斯特拉大学 | 鱼精蛋白纳米胶囊 |
CN106491526A (zh) * | 2016-11-14 | 2017-03-15 | 暨南大学 | 一种药物缓释型复合滴眼液及其制备方法与应用 |
CN113750078A (zh) * | 2021-09-10 | 2021-12-07 | 华中药业股份有限公司 | 一种布洛芬速释缓释纳米粒及其制备方法 |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080311177A1 (en) | 2007-06-14 | 2008-12-18 | Massachusetts Institute Of Technology | Self Assembled Films for Protein and Drug Delivery Applications |
EP2113257A1 (en) * | 2008-04-30 | 2009-11-04 | Consorzio per il Centro di Biomedica Moleculare Scrl | Polyelectrolyte with positive net charge for use as medicament and diagnostic for cancer |
US9198875B2 (en) * | 2008-08-17 | 2015-12-01 | Massachusetts Institute Of Technology | Controlled delivery of bioactive agents from decomposable films |
WO2010042212A2 (en) * | 2008-10-10 | 2010-04-15 | Dara Biosciences, Inc. | Methods for treating or preventing pain using spicamycin derivatives |
US9277999B2 (en) | 2009-02-27 | 2016-03-08 | University of Pittsburgh—of the Commonwealth System of Higher Education | Joint bioscaffolds |
WO2010111517A1 (en) * | 2009-03-25 | 2010-09-30 | Northeastern University | Stable polyelectrolyte coated nanoparticles |
FR2943544B1 (fr) * | 2009-03-31 | 2012-04-20 | Univ Angers | Procede de preparation de capsules lipidiques fonctionnalisees. |
WO2011019954A2 (en) * | 2009-08-13 | 2011-02-17 | Yehuda Ivri | Intracochlear drug delivery to the central nervous system |
US20130039864A1 (en) * | 2010-04-23 | 2013-02-14 | Francois Ravenelle | Non-Intravenous Dosage Form Comprising Solid Formulation of Liquid Biologically Active Agent and Uses Thereof |
AU2011336352B2 (en) | 2010-12-02 | 2015-05-28 | Greenmark Biomedical Inc. | Aptamer bioconjugate drug delivery device |
US8795643B1 (en) * | 2011-04-29 | 2014-08-05 | Michael Mark Anthony | Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution |
US9078818B1 (en) * | 2011-04-29 | 2015-07-14 | Michael Mark Anthony | Method of preparing a hair treatment formulation comprising nanoparticles in solution and method of hair treatment utilizing a treatment formulation comprising nanoparticles in solution |
US20130084312A1 (en) * | 2011-06-13 | 2013-04-04 | Rose Pharmaceuticals, Llc | Nanoparticles for delivery of bioactive agents |
WO2013033513A1 (en) | 2011-08-31 | 2013-03-07 | University Of Georgia Research Foundation, Inc. | Apoptosis-targeting nanoparticles |
JP6356614B2 (ja) | 2012-02-17 | 2018-07-11 | ユニバーシティ・オブ・ジョージア・リサーチ・ファウンデイション・インコーポレイテッド | 薬剤のミトコンドリア輸送のためのナノ粒子 |
EP2841056A4 (en) * | 2012-04-23 | 2015-09-16 | Massachusetts Inst Technology | COATED PARTICLES LAYER BY LAYER STABLE |
CA2790763A1 (en) * | 2012-05-31 | 2013-11-30 | Ecosynthetix Ltd. | Aptamer bioconjugate drug delivery device |
CA2889693C (en) * | 2012-10-30 | 2021-07-13 | Particle Sciences, Inc. | Drug delivery particle formulations with targeting moieties |
SG10201706968UA (en) * | 2013-02-05 | 2017-09-28 | 1Globe Health Inst Llc | Biodegradable and clinically-compatible nanoparticles as drug delivery carriers |
WO2014134029A1 (en) | 2013-02-26 | 2014-09-04 | Massachusetts Institute Of Technology | Nucleic acid particles, methods and use thereof |
WO2014150074A1 (en) | 2013-03-15 | 2014-09-25 | Massachusetts Institute Of Technology | Compositions and methods for nucleic acid delivery |
WO2015031059A1 (en) * | 2013-08-26 | 2015-03-05 | The Trustees Of The University Of Pennsylvania | Ph-sensitive peptides and their nanoparticles for drug delivery |
WO2015065773A1 (en) * | 2013-11-04 | 2015-05-07 | Northeastern University | System for co-delivery of polynucleotides and drugs into protease-expressing cells |
US10398663B2 (en) | 2014-03-14 | 2019-09-03 | University Of Georgia Research Foundation, Inc. | Mitochondrial delivery of 3-bromopyruvate |
HU231076B1 (hu) | 2015-07-31 | 2020-06-29 | Szegedi Tudományegyetem | Hatóanyagoknak a központi idegrendszerben történő szabályozott leadására alkalmas nanokompozit, eljárás annak előállítására és alkalmazása |
EP3426301A4 (en) * | 2016-03-08 | 2019-11-06 | Los Gatos Pharmaceuticals, Inc. | VERBUNDNANOPARTICLES AND USES THEREOF |
WO2017165506A1 (en) * | 2016-03-23 | 2017-09-28 | Academia Sinica | Thin-shell polymeric nanoparticles and uses thereof |
WO2019089567A1 (en) | 2017-10-30 | 2019-05-09 | Massachusetts Institute Of Technology | Layer-by-layer nanoparticles for cytokine therapy in cancer treatment |
CN111918675A (zh) | 2018-03-28 | 2020-11-10 | 格林马克生物医药股份有限公司 | 磷酸盐交联淀粉纳米颗粒和牙科治疗 |
CA3101410A1 (en) * | 2018-06-15 | 2019-12-19 | Croma-Pharma Gmbh | Stabilized hyaluronic acid |
CN113710806A (zh) * | 2019-02-08 | 2021-11-26 | 俄亥俄州创新基金会 | 用于眼部施用治疗剂的药物递送组合物以及其使用方法 |
US12018315B2 (en) | 2019-05-30 | 2024-06-25 | Massachusetts Institute Of Technology | Peptide nucleic acid functionalized hydrogel microneedles for sampling and detection of interstitial fluid nucleic acids |
WO2024178502A1 (en) * | 2023-02-27 | 2024-09-06 | Valorisation Hsj, Limited Partnership | Layer-by-layer modified lipid nanoparticles, uses thereof and methods for producing the same |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69904307T2 (de) * | 1998-03-19 | 2003-09-04 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | Herstellung von mit mehrlagen gestrichenen partikeln und hohlen schalen durch elektrostatische selbstorganisierung von nanokompositmehrlagen auf zersetzbaren schablonen |
DE102004059792A1 (de) * | 2004-12-10 | 2006-06-14 | Röhm GmbH & Co. KG | Multipartikuläre Arzneiform, enthaltend mucoadhaesiv formulierte Nukleinsäure-Wirkstoffe, sowie ein Verfahren zur Herstellung der Arzneiform |
US20090061006A1 (en) * | 2006-03-31 | 2009-03-05 | Carola Leuschner | Layered Nanoparticles for Sustained Release of Small Molecules |
-
2008
- 2008-07-16 CN CN200880024841A patent/CN101801358A/zh active Pending
- 2008-07-16 US US12/669,395 patent/US20110038939A1/en not_active Abandoned
- 2008-07-16 JP JP2010517133A patent/JP2010533730A/ja active Pending
- 2008-07-16 WO PCT/US2008/070164 patent/WO2009012303A2/en active Application Filing
- 2008-07-16 CA CA2694089A patent/CA2694089A1/en not_active Abandoned
- 2008-07-16 EP EP08826426A patent/EP2164475A2/en not_active Withdrawn
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102175655A (zh) * | 2010-12-24 | 2011-09-07 | 东南大学 | 一种双模式光学成像探针及其制备方法 |
CN102175655B (zh) * | 2010-12-24 | 2013-10-30 | 东南大学 | 一种双模式光学成像探针及其制备方法 |
CN105283176A (zh) * | 2012-12-17 | 2016-01-27 | 圣地亚哥-德孔波斯特拉大学 | 鱼精蛋白纳米胶囊 |
CN106491526A (zh) * | 2016-11-14 | 2017-03-15 | 暨南大学 | 一种药物缓释型复合滴眼液及其制备方法与应用 |
CN106491526B (zh) * | 2016-11-14 | 2019-03-22 | 暨南大学 | 一种药物缓释型复合滴眼液及其制备方法与应用 |
CN113750078A (zh) * | 2021-09-10 | 2021-12-07 | 华中药业股份有限公司 | 一种布洛芬速释缓释纳米粒及其制备方法 |
CN113750078B (zh) * | 2021-09-10 | 2023-10-10 | 华中药业股份有限公司 | 一种布洛芬速释缓释纳米粒及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CA2694089A1 (en) | 2009-01-22 |
WO2009012303A3 (en) | 2010-08-12 |
WO2009012303A2 (en) | 2009-01-22 |
JP2010533730A (ja) | 2010-10-28 |
EP2164475A2 (en) | 2010-03-24 |
US20110038939A1 (en) | 2011-02-17 |
WO2009012303A9 (en) | 2009-03-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101801358A (zh) | 治疗性稳定的纳米颗粒 | |
Jain et al. | Protein nanoparticles: promising platforms for drug delivery applications | |
Gao et al. | Coating nanoparticles with cell membranes for targeted drug delivery | |
Chakroun et al. | Fine-tuning the linear release rate of paclitaxel-bearing supramolecular filament hydrogels through molecular engineering | |
KR100789008B1 (ko) | 신규 약물 제제 | |
MaHam et al. | Protein‐based nanomedicine platforms for drug delivery | |
Gao et al. | Liposome-like nanostructures for drug delivery | |
Gardner et al. | Biomaterials‐based modulation of the immune system | |
Zhang et al. | Surface loading of nanoparticles on engineered or natural erythrocytes for prolonged circulation time: strategies and applications | |
Gupta et al. | Dual targeted polymeric nanoparticles based on tumor endothelium and tumor cells for enhanced antitumor drug delivery | |
Xie et al. | Immunoengineering with biomaterials for enhanced cancer immunotherapy | |
Chopra et al. | Design of insulin-loaded nanoparticles enabled by multistep control of nanoprecipitation and zinc chelation | |
JP2019504895A (ja) | スギ花粉エピトープを封入するtimp(組織性メタロプロテアーゼ阻害因子) | |
Silvestre et al. | Monoclonal antibodies carried in drug delivery nanosystems as a strategy for cancer treatment | |
Eras et al. | Chemical conjugation in drug delivery systems | |
Hersh et al. | Peptide-modified biopolymers for biomedical applications | |
JP2019537600A (ja) | ポリマーナノ粒子 | |
Pei et al. | Materials-based drug delivery approaches: Recent advances and future perspectives | |
Caliceti et al. | Advances in drug delivery and biomaterials: Facts and vision | |
Thakur et al. | Recent trends in targeted drug delivery | |
KR101180181B1 (ko) | 나노 입자 및 그의 제조 방법 | |
Bajwa et al. | Scale-up, Preclinical and Clinical Status of Poly (Lactide-Co-Glycolide) and its Copolymers based Drug Delivery Systems | |
Gagliardi et al. | Bio-inspired nanoparticles as drug delivery vectors | |
Neamtu et al. | Design and applications of polymer-like peptides in biomedical nanogels | |
Jaganathan | Bioresorbable polyelectrolytes for smuggling drugs into cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
ASS | Succession or assignment of patent right |
Owner name: LOUISIANA TECH. UNIVERSITY BRANCH FOUNDATION, LOUI |
|
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20110428 Address after: Massachusetts USA Applicant after: Northeastern University Co-applicant after: Louisiana Tech University research foundation, Louisiana Tech University Foundation Address before: Massachusetts USA Applicant before: Northeastern University |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1150330 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Open date: 20100811 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1150330 Country of ref document: HK |